Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

The Department of Oncology has signed up to collaborate with Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T cell enhancing therapeutics.

Oncology logo blue

This collaboration will accelerate the development of CB307, Crescendo’s lead programme for PSMA positive tumours, and its follow on pipeline of CD137-directed T cell enhancing programmes.


The Department’s Human Tissue Facility, led by Dr Kerry Fisher, focuses on deepening our understanding of the tumour microenvironment to develop innovative new therapies for cancer patients.


Dr Kerry Fisher, Department of Oncology, University of Oxford, commented:

“We look forward to working with Crescendo to further explore and understand the mechanisms driving the development of cancers and applying our group’s translational expertise to advance Crescendo’s novel Humabody® programmes.”

 

Full details on the Crescendo Biologics news page